Castle Biosciences (CSTL) Other financing activities (2018 - 2026)

Castle Biosciences has reported Other financing activities for 9 years, with the latest figure at $836000.0 in Q2 2026.

• Quarterly Other financing activities rose 63.28% year-over-year to $836000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.0 million (up 11.9% YoY) and the FY2025 annual result came in at $2.4 million, down 18.95% from the prior year.
• Other financing activities slipped to $836000.0 in Q2 2026 per CSTL's latest filing, from $1.3 million in the prior quarter.
• Over five years, Other financing activities peaked at $1.3 million in Q1 2026 and troughed at $220000.0 in Q3 2025.
• A 5-year average of $705611.1 and a median of $681000.0 in 2022 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 85.79% in 2022, down 80.24% in 2022.
• Over 5 years, Other financing activities stood at $680000.0 in 2022, then rose by 0.29% to $682000.0 in 2023, then decreased by 5.13% to $647000.0 in 2024, then advanced by 10.36% to $714000.0 in 2025, then climbed by 17.09% to $836000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $836000.0, $1.3 million, and $714000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.